124 related articles for article (PubMed ID: 11300338)
1. Complete response of an HIV negative gastric Kaposi's sarcoma (KS) patient with peritoneal carcinomatosis by liposomal daunorubicin treatment.
Fléchon A; Lombard-Bohas C; Boulez J; Blay JY; Scoazec JY
Ann Oncol; 2001 Feb; 12(2):275-6. PubMed ID: 11300338
[TBL] [Abstract][Full Text] [Related]
2. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma.
Uthayakumar S; Bower M; Money-Kyrle J; Muyshondt C; Youle M; Hannon F; Phillips R; Gazzard BG; Boag F
AIDS; 1996 May; 10(5):515-9. PubMed ID: 8724043
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma.
Chew T; Jacobs M
Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma.
Tulpule A; Yung RC; Wernz J; Espina BM; Myers A; Scadden DT; Cabriales S; Ilaw M; Boswell W; Gill PS
J Clin Oncol; 1998 Oct; 16(10):3369-74. PubMed ID: 9779714
[TBL] [Abstract][Full Text] [Related]
5. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of AIDS-related pulmonary Kaposi's sarcoma with liposomal daunorubicin.
Schürmann D; Dormann A; Grünewald T; Ruf B
Eur Respir J; 1994 Apr; 7(4):824-5. PubMed ID: 8005268
[TBL] [Abstract][Full Text] [Related]
7. Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma.
Am J Health Syst Pharm; 1996 Jul; 53(13):1500, 1505. PubMed ID: 8809269
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
Bennett CL; Golub RM; Stinson TJ; Aboulafia DM; von Roenn J; Bogner J; Goebel FD; Stewart S
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):460-5. PubMed ID: 9715842
[TBL] [Abstract][Full Text] [Related]
9. Liposomal daunorubicin: new preparation. Kaposi's sarcoma: occasional remission.
Prescrire Int; 1998 Apr; 7(34):41-2. PubMed ID: 10183380
[TBL] [Abstract][Full Text] [Related]
10. Liposomal daunorubicin as treatment for Kaposi's sarcoma.
Petre CE; Dittmer DP
Int J Nanomedicine; 2007; 2(3):277-88. PubMed ID: 18019828
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
Hjortsberg C; Persson U; Lidbrink E; Bennett C
Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764
[TBL] [Abstract][Full Text] [Related]
13. Liposomal drug targeting in the treatment of Kaposi's sarcoma.
Wernz JC
AIDS Patient Care STDS; 1996 Dec; 10(6):362-7. PubMed ID: 11361553
[No Abstract] [Full Text] [Related]
14. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
[TBL] [Abstract][Full Text] [Related]
15. Use of liposomal anthracyclines in Kaposi's sarcoma.
Krown SE; Northfelt DW; Osoba D; Stewart JS
Semin Oncol; 2004 Dec; 31(6 Suppl 13):36-52. PubMed ID: 15717737
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.
Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG
AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866
[TBL] [Abstract][Full Text] [Related]
17. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma.
Presant CA; Scolaro M; Kennedy P; Blayney DW; Flanagan B; Lisak J; Presant J
Lancet; 1993 May; 341(8855):1242-3. PubMed ID: 8098393
[TBL] [Abstract][Full Text] [Related]
18. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.
Money-Kyrle JF; Bates F; Ready J; Gazzard BG; Phillips RH; Boag FC
Clin Oncol (R Coll Radiol); 1993; 5(6):367-71. PubMed ID: 8305357
[TBL] [Abstract][Full Text] [Related]
19. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
White RM
AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
[No Abstract] [Full Text] [Related]
20. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Goebel FD; Jablonowski H
Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
